Fwd: Recommended articles

[Okechukwu Ogah]

Dr O.S Ogah. MBBS, MSc, PhD, MD, FWACP, FACP, FESC, FNCS

A. Senior Lecturer

Cardiology Unit, Department of Medicine,

Faculty of Clinical Sciences

College of Medicine,

University of Ibadan, NIGERIA

B. Honorary Consultant Physician/Cardiologist,

Cardiology Unit,

Department of Medicine

University College Hospital Ibadan, NIGERIA

PERSONAL POSTAL ADDRESS

P.O BOX 14343, UNIVERSITY OF IBADAN  POST OFFICE

IBADAN, NIGERIA

Tel. +234 806 77 47 121
Fax. +1215-975-6817 (Electronic)
Emails: 

oso...@com.ui.edu.ng ,

osoga...@gmail.com

osoga...@yahoo.com

https://www.researchgate.net/profile/Okechukwu_Ogah4/contributions

C. Bernard Lown Visiting Scholar in Cardiovascular Health

Department of Global Health and Population

Harvard T.H. Chan School of Public Health

Email: oo...@hsph.harvard.edu

D. Adjunct Researcher,

Institute of Advanced Medical Research and Training (IAMRAT)

College of Medicine, University of Ibadan, NIGERIA

E. Affiliate Member,

The Hatter Institute for Cardiovascular Research in Africa (HICRA)

4th Floor Chris Barnard Building
Faculty of Health Sciences
University of Cape Town
Private Bag X3 7935
Observatory, SOUTH AFRICA

http://www.hatter.uct.ac.za/icra/about/staff/visiting-researchers

F. Past President,

Nigerian Cardiac Society

--------------------------------------------------------------------------------------------------------------------------------------------------

"For with thee is the fountain of life: in thy light shall we see light." Psalm 36:9

-------------------------------------------------------------------------------------------------

---------- Forwarded message ---------
From: Google Scholar Alerts <scholarale...@google.com>
Date: Sat, Mar 9, 2024 at 11:05 PM
Subject: Recommended articles
To: <osoga...@gmail.com>

[PDF] Impairment of the adrenergic reserve associated with exercise intolerance in a murine model of heart failure with preserved ejection fraction

L Semmler, T Jeising, J Huettemeister, M Bathe‐Peters… - Acta Physiologica, 2024

Aim Exercise intolerance is the central symptom in patients with heart failure with
preserved ejection fraction. In the present study, we investigated the adrenergic
reserve both in vivo and in cardiomyocytes of a murine cardiometabolic HFpEF …

Clinical characteristics and long-term outcomes of patients with heart failure with improved ejection fraction. First polish experience from LECRA-HF registry

K Stępień, K Nowak, N Kachnic, A Karcińska… - Advances in Medical …, 2024

Purpose Heart failure (HF) with improved ejection fraction (HFimpEF) is a new
category of HF introduced in the newest European Society of Cardiology guidelines.
However, clinical characteristics and long-term outcomes of HFimpEF patients …

[HTML] Obesity Paradox in Heart Failure with Mildly Reduced Ejection Fraction

M Reinhardt, T Schupp, M Abumayyaleh, F Lau… - Pragmatic and …, 2024

Objective The study investigates the prognostic impact of body mass index (BMI) in
patients hospitalized with heart failure with mildly reduced ejection fraction
(HFmrEF). Background Limited data regarding the prognostic impact of BMI in …

Incidence and predictors of left atrial thrombus in patients with atrial fibrillation under anticoagulation therapy

JM Lee, MJ Cha, GB Nam, KJ Choi, BJ Sun, DH Kim… - Clinical Research in …, 2024

Objective To investigate the incidence and associated factors of LAT in patients with
atrial fibrillation (AF) who had been receiving anticoagulation therapy for more than 4
weeks, and to develop a prediction model using clinical and echocardiographic …

Comparative analysis of hospitalization risk for incident heart failure in non‐Hispanic Black versus non‐Hispanic White individuals with type 2 diabetes on …

BM Mishriky, DM Cummings, Y Fu, JR Halladay… - Diabetes, Obesity and …, 2024

Aim There are limited data to evaluate hospitalization for heart failure (hHF) in non‐
Hispanic Black (hereafter Black) or non‐Hispanic White (hereafter White) individuals
without previous hHF. Our goal was to evaluate the risk of hHF among Black versus …

[PDF] Slow blood-flow in the left atrial appendage is associated with stroke in atrial fibrillation patients

N Paliwal, HC Park, Y Mao, SJ Hong, Y Lee… - Heliyon, 2024

Abstract Background and Purpose: Atrial fibrillation (AF) patients are at high risk of
stroke with∼ 90% clots originating from the left atrial appendage (LAA). Clinical
understanding of blood-flow based parameters and their potential association with …

Secular Trends in Outcomes and Impact of Novel Oral Anticoagulants in Atrial Fibrillation–Related Acute Ischemic Stroke

M Lee, BC Lee, KH Yu, MS Oh, BJ Kim, JY Kim, J Kang… - Stroke, 2024

Background: Novel oral anticoagulants (NOACs) are currently recommended for the
secondary prevention of stroke in patients with acute ischemic stroke (AIS)
accompanied by atrial fibrillation (AF). However, the impact of NOACs on clinical …

[HTML] Mortality after major bleeding in Asian atrial fibrillation patients receiving different direct oral anticoagulants: a nationwide, propensity score study

JH Yu, PR Li, DY Chen, WK Huang, LC See - Scientific Reports, 2024

In this research, we assessed mortality after major bleeding events in atrial fibrillation
(AF) patients taking four direct oral anticoagulants (DOACs). Drawing data from the
Taiwan National Health Insurance Research Database between 2016 and 2019, we …

Angiotensin receptor-neprilysin inhibition in patients with STEMI vs NSTEMI

DL Mann, J Nicolas, B Claggett, ZM Miao, CB Granger… - Journal of the American …, 2024

Background Patients who sustain an acute myocardial infarction (AMI), including ST-
segment elevation myocardial infarction (STEMI) and non–ST-segment elevation
myocardial infarction (NSTEMI), remain at high risk for heart failure (HF), coronary …

Comparative effectiveness of factor Xa non-vitamin K antagonist oral anticoagulants versus phenprocoumon in patients with non-valvular atrial fibrillation

R Kreutz, S Kloss, D Enders, K Abdelgawwad, D Häckl… - International Journal of …, 2024

Background Non-vitamin K antagonist oral anticoagulants (NOACs) have largely
supplanted vitamin K antagonists (VKAs) for oral anticoagulation in non-valvular
atrial fibrillation (NVAF). However, data on the real-world effectiveness of NOACs vs …

See all recommendations

 

This message was sent by Google Scholar because you're following new recommended articles for your profile.

List alerts

Cancel alert

[Okechukwu Ogah]

fyi

[PDF] Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Angiotensin Receptor‐Neprilysin Inhibitors in Patients With Atrial Fibrillation and Heart Failure From 2021 to …

A Alonso, AA Morris, AI Naimi, AB Alam, L Li… - Journal of the American …, 2024

Background Contemporary use of sodium‐glucose cotransporter‐2 inhibitors
(SGLT2i) and angiotensin receptor‐neprilysin inhibitors (ARNi) in patients with atrial
fibrillation (AF) and heart failure (HF) has not been described. Methods and Results …

Blood pressure and intensive treatment up‐titration after acute heart failure hospitalization: Insights from the STRONG‐HF trial

M Pagnesi, OAG Vilamajó, A Meiriño, CA Dumont… - European Journal of Heart …, 2024

Aims A high‐intensity care (HIC) strategy with rapid guideline‐directed medical
therapy (GDMT) up‐titration and close follow‐up visits improved outcomes,
compared to usual care (UC), in patients recently hospitalized for acute heart failure …

[PDF] Prognostic impact of oral anticoagulation therapy and atrial fibrillation in patients with type B acute aortic dissection

N Ishizue, H Fukaya, J Oikawa, N Sato, S Ogiso… - Journal of Arrhythmia

Background The prognostic impact of atrial fibrillation (AF) and oral anticoagulation
(OAC) therapy in patients with type B acute aortic dissection (AAD) remains unclear.
Therefore, we investigated the prognostic impact of AF and OAC therapy in patients …

[HTML] Structural and Functional Impact of Adrenoceptor Beta-1 Gene Polymorphism in Patients with Hypertrophic Cardiomyopathy and Response to Beta-Blocker Therapy

D Raimoglou, C İzgi, R Enar, MH Karpuz, B Karadağ… - Anatolian Journal of …, 2024

Background: Hypertrophic cardiomyopathy (HCM) is a genetically inherited cardiac
disorder with diverse clinical presentations. Adrenergic activity, primarily mediated
through beta-adrenoceptors, plays a central role in the clinical course of HCM …

Nature and Magnitude of the Benefits of Dapagliflozin and Empagliflozin for Heart Failure

JGF Cleland - Circulation, 2024

For HFpEF, the trials found that SGLT2i prevented only 2 to 3 worsening heart failure
events per 100 patientyears of treatment and had little or no effect on mortality, apart
from a subgroup of patients who previously had reduced ejection fraction. 8 For …

[Okechukwu Ogah]

[HTML] Previous heart failure hospitalization, spironolactone and outcomes in heart failure with preserved ejection fraction–a secondary analysis of TOPCAT

B Szabo, L Benson, G Savarese, C Hage, M Fudim… - American Heart Journal, 2024

Background Hospitalization for heart failure (HHF) is associated with poor post-
discharge outcomes but the role of time since most recent HHF and potential
treatment interactions are unknown. We aimed to assess history of and time since …

[PDF] Relationship of Warfarin and Apixaban with Vascular Function in Patients with Atrial Fibrillation

RT Junejo, D Gupta, RL Snowdon, GYH Lip, JP Fisher - Journal of Vascular …, 2024

Introduction: Atrial fibrillation (AF) is associated with endothelial damage/dysfunction.
Herein, we tested the hypothesis that brachial artery flow-mediated dilation (FMD) is
superior in AF patients taking apixaban compared to warfarin. Methods: AF patients …

[HTML] Effect of sacubitril/valsartan on the hypertensive heart in continuous light-induced and lactacystin-induced pre-hypertension: Interactions with the renin-angiotensin …

F Simko, P Stanko, K Repova, T Baka, K Krajcirovicova… - Biomedicine & …, 2024

This study investigated whether sacubitril/valsartan or valsartan are able to prevent
left ventricular (LV) fibrotic remodelling and dysfunction in two experimental models
of pre-hypertension induced by continuous light (24 hours/day) exposure or by …

[PDF] Systemic Vascular Resistance and Myocardial Work Analysis in Hypertrophic Cardiomyopathy and Transthyretin Cardiac Amyloidosis with Preserved Left Ventricular …

C De Gregorio, G Trimarchi, DC Faro, C Poleggi… - 2024

The impact of systemic vascular resistance (SVR) in hypertrophic (HCM) and amyloid
cardio-myopathies has been seldom investigated. We studied pressure-strain loop
derived myocardial work (MW) indices and SVR in patients with either sarcomere …

[Okechukwu Ogah]

[PDF] The effect of kidney function on guideline‐directed medical therapy implementation and prognosis in heart failure with reduced ejection fraction

F Bánfi‐Bacsárdi, D Pilecky, M Vámos, Z Majoros… - Clinical Cardiology, 2024

Background Kidney dysfunction (KD) is a main limiting factor of applying guideline‐
directed medical therapy (GDMT) and reaching the recommended target doses (TD)
in heart failure (HF) with reduced ejection fraction (HFrEF). Hypothesis We aimed to …

[PDF] Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA‐HF and DELIVER

A Peikert, M Vaduganathan, BL Claggett, IJ Kulac… - European Journal of Heart …, 2024

Aims Patients with heart failure (HF) and history of myocardial infarction (MI) face a
higher risk of disease progression and clinical events. Whether sodium–glucose
cotransporter 2 inhibitors may modify clinical trajectory in such individuals remains …

[PDF] Cytokines, C-Reactive Protein, and Risk of Incident Hypertension in the REGARDS Study

TB Plante, SP Juraschek, G Howard, VJ Howard… - Hypertension, 2024

BACKGROUND: Hypertension is a highly prevalent cardiovascular disease risk
factor that may be related to inflammation. Whether adverse levels of specific
inflammatory cytokines relate to hypertension is unknown. The present study sought …